Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Ross Moat Sells 27,977 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 27,977 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.36, for a total value of $2,583,955.72. Following the completion of the sale, the chief operating officer owned 10,294 shares of the company’s stock, valued at approximately $950,753.84. This trade represents a 73.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Friday, October 30th, Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $93.13, for a total transaction of $7,041,373.04.

Kiniksa Pharmaceuticals International Trading Up 3.0%

Shares of Kiniksa Pharmaceuticals International stock opened at $96.11 on Thursday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $98.48. The stock has a market cap of $7.50 billion, a PE ratio of 73.93 and a beta of 0.07. The company’s 50-day moving average price is $79.99 and its two-hundred day moving average price is $60.85.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Zacks identified KNSA as a strong momentum stock, supporting the view that recent trading and performance trends remain favorable. The company’s latest reported quarterly results also beat analyst expectations for both earnings and revenue. Zacks momentum article
• Negative Sentiment: CEO Sanj Patel and other senior insiders, including the CFO, COO, CAO and John Paolini, disclosed substantial stock sales. Such selling can raise concerns about insider confidence or add selling pressure, although the reported transactions were conducted under pre-arranged Rule 10b5-1 plans. CEO SEC filing Insider sale report

Analysts Set New Price Targets

Several research firms have issued reports on KNSA. Canaccord Genuity Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $100.57.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently modified their holdings of KNSA. Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA raised its position in Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after acquiring an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares during the last quarter. Spruce Street Capital LP lifted its stake in Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.